Vincere Biosciences secures $2.7 million NIH funding to progress its USP30 inhibitor for acute kidney injury treatment
Executive summary: Vincere Biosciences received a $2.7 million SBIR Phase II grant from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The funding facilitates the IND-enabling stage for a USP30 inhibitor, a key step in moving a novel therapeutic for acute kidney injury (AKI) toward clinical testing.
Who is involved: Vincere Biosciences and the National Institutes of Health (NIH/NIDDK).
Likely next: Completion of IND-enabling studies to allow for upcoming regulatory filings for human clinical trials.
Vincere Biosciences has been awarded a Phase II SBIR grant from the NIDDK to advance its small molecule USP30 inhibitor. This federal funding is specifically earmarked for IND-enabling development, a critical milestone required to transition from laboratory research to human clinical trials. The focus on mitochondrial dysfunction marks a specialized approach to treating acute kidney injury (AKI).
What's next — scenarios
Base: Successful IND filing (60%)
Vincere transitions to Phase I clinical trials, increasing company valuation and attracting private biotech investment.
- Successful completion of toxicology studies
- FDA acceptance of IND application
Downside: Technical hurdles in IND-enabling phase (25%)
Development delays or requirement for additional studies, depleting grant capital without reaching clinical milestones.
- Safety signals in non-clinical models
- Failure to meet pharmacokinetic thresholds
Upside: Strategic partnership/M&A (15%)
A larger pharmaceutical company acquires Vincere to add the USP30 inhibitor to their renal pipeline.
- Strong efficacy data in preclinical models
- Interest from major renal-focused big pharma players
What to watch
- Publication of preclinical efficacy data for the USP30 inhibitor
- Completion of IND-enabling studies (timeline subject to study design)
- Any subsequent non-dilutive funding or private equity rounds
Timeline
- — Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury (PR Newswire)
- — Partillion Bioscience Secures $2.1 Million NIH SBIR Grant (PR Newswire)
- — Primrose Bio Awarded NIH Grant to Develop Genetic Medicine (PR Newswire)
Analysis — what this means
Likely next events
- IND-enabling study milestones (expected within the grant period)
- Potential Phase I trial commencement following FDA clearance
Sectors affected
- Biotechnology
- Pharmaceuticals (Renal/Nephrology)
- Clinical Research Organizations (CROs)
Regulatory implications
- Requirement for IND (Investigational New Drug) filing with the FDA to proceed to human trials
Historical parallels
- Partillion Bioscience SBIR award (Sept 2026) for cell sequencing
- Primrose Bio NIH grant (July 2026) for genetic medicine technology
Key entities
Sources
- Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury — PR Newswire
- Partillion Bioscience Secures $2.1 Million NIH SBIR Grant — PR Newswire
- Primrose Bio Awarded NIH Grant to Develop Genetic Medicine — PR Newswire